Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 5016-5028

  Merindol, Natacha ^a,b,c   Fourati, Insaf Salem ^a,b,c   Brito, Rose Marie ^b,d   Grenier, Anne Julie ^a,b,c   Charrier, Emily ^b,c   Cordeiro, Paulo ^b   Caty, Martine ^a   Mezziani, Samira ^b,d   Malette, Brigitte ^b,d   Duval, Michel ^b,c,d   Alfieri, Carolina ^b,c   Ovetchkine, Philippe ^b,c,d   Deist, Françoise Le ^b,c,d   Soudeyns, Hugo ^b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Centre de Cancerologie Charles Bruneau   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; GAMMA INTERFERON; GANCICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; INFANT; INFECTION PREVENTION; INFECTION RISK; MALE; MYELODYSPLASTIC SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CHICKENPOX; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENETIC DISEASES, INBORN; HEMATOLOGIC DISEASES; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; INTERFERON-GAMMA; MALE; RECOVERY OF FUNCTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84868541002     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201759     Document Type: Article

References (81)

1. Lin, S. J., D. C. Yan, Y. C. Lee, H. S. Hsiao, P. T. Lee, Y. W. Liang, and M. L. Kuo. 2012. Umbilical cord blood immunology: relevance to stem cell transplantation. Clin. Rev. Allergy Immunol. 42: 45-57.
2. Theilgaard-Mönch, K., K. Raaschou-Jensen, H. Palm, K. Schjødt, C. Heilmann, L. Vindeløv, N. Jacobsen, and E. Dickmeiss. 2001. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant. 28: 1073-1082.
3. Godfrey, W. R., D. J. Spoden, Y. G. Ge, S. R. Baker, B. Liu, B. L. Levine, C. H. June, B. R. Blazar, and S. B. Porter. 2005. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105: 750-758.
4. Wagner, J. E., J. Rosenthal, R. Sweetman, X. O. Shu, S. M. Davies, N. K. Ramsay, P. B. McGlave, L. Sender, and M. S. Cairo. 1996. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 88: 795-802.
5. Rocha, V., J. Cornish, E. L. Sievers, A. Filipovich, F. Locatelli, C. Peters, M. Remberger, G. Michel, W. Arcese, S. Dallorso, et al. 2001. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97: 2962-2971.
6. Thomson, B. G., K. A. Robertson, D. Gowan, D. Heilman, H. E. Broxmeyer, D. Emanuel, P. Kotylo, Z. Brahmi, and F. O. Smith. 2000. Analysis of en-graftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 96: 2703-2711.
7. Barker, J. N., R. E. Hough, J. A. van Burik, T. E. DeFor, M. L. MacMillan, M. R. O'Brien, and J. E. Wagner. 2005. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol. Blood Marrow Transplant. 11: 362-370.
8. Merindol, N., E. Charrier, M. Duval, and H. Soudeyns. 2011. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J. Leukoc. Biol. 90: 49-60.
9. Vandenbosch, K., P. Ovetchkine, M. A. Champagne, E. Haddad, L. Alexandrov, and M. Duval. 2008. Varicella-zoster virus disease is more frequent after cord blood than after bone marrow transplantation. Biol. Blood Marrow Transplant. 14: 867-871.
10. Beck, J. C., J. E. Wagner, T. E. DeFor, C. G. Brunstein, M. R. Schleiss, J. A. Young, D. H. Weisdorf, S. Cooley, J. S. Miller, and M. R. Verneris. 2010. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol. Blood Marrow Transplant. 16: 215-222.
11. Ljungman, P., M. Hakki, and M. Boeckh. 2010. Cytomegalovirus in hemato-poietic stem cell transplant recipients. Infect. Dis. Clin. North Am. 24: 319-337.
12. Takami, A., K. Mochizuki, H. Asakura, H. Yamazaki, H. Okumura, and S. Nakao. 2005. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica 90: 1290-1292.
13. Tomonari, A., S. Takahashi, J. Ooi, N. Tsukada, T. Konuma, S. Kato, S. Kasahara, T. Iseki, T. Yamaguchi, A. Tojo, and S. Asano. 2008. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur. J. Haematol. 80: 251-257.
14. Uchida, N., A. Wake, S. Takagi, H. Yamamoto, D. Kato, Y. Matsuhashi, T. Matsumura, S. Seo, N. Matsuno, K. Masuoka, et al. 2008. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol. Blood Marrow Transplant. 14: 583-590.
15. Goodrich, J. M., R. A. Bowden, L. Fisher, C. Keller, G. Schoch, and J. D. Meyers. 1993. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118: 173-178.
16. Boeckh, M., T. A. Gooley, D. Myerson, T. Cunningham, G. Schoch, and R. A. Bowden. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88: 4063-4071.
17. Salzberger, B., R. A. Bowden, R. C. Hackman, C. Davis, and M. Boeckh. 1997. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 90: 2502-2508.
18. Boeckh, M., W. G. Nichols, G. Papanicolaou, R. Rubin, J. R. Wingard, and J. Zaia. 2003. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 9: 543-558.
19. Matsumura, T., H. Narimatsu, M. Kami, K. Yuji, E. Kusumi, A. Hori, N. Murashige, Y. Tanaka, K. Masuoka, A. Wake, et al. 2007. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol. Blood Marrow Transplant. 13: 577-583.
20. Boeckh, M., and W. G. Nichols. 2004. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008.
21. Hebart, H., and H. Einsele. 2004. Clinical aspects of CMV infection after stem cell transplantation. Hum. Immunol. 65: 432-436.
22. Walker, C. M., J. A. van Burik, T. E. De For, and D. J. Weisdorf. 2007. Cyto-megalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol. Blood Marrow Transplant. 13: 1106-1115.
23. Zaia, J. A. 2002. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin. Infect. Dis. 35: 999-1004.
24. Gratama, J. W., M. Boeckh, R. Nakamura, J. J. Cornelissen, R. A. Brooimans, J. A. Zaia, S. J. Forman, K. Gaal, K. R. Bray, G. H. Gasior, et al. 2010. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116: 1655-1662.
25. Pastore, D., M. Delia, A. Mestice, T. Perrone, P. Carluccio, F. Gaudio, A. Giordano, A. R. Rossi, A. Ricco, M. Leo, et al. 2011. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 17: 550-557.
26. + T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 45: 543-549.
27. Tormo, N., C. Solano, I. Benet, J. Nieto, R. de la Cámara, J. López, A. Garcia-Noblejas, B. Muñoz-Cobo, E. Costa, M. A. Clari, et al. 2011. Reconstitution of CMV pp65 and IE-1-specific IFN-g CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant. 46: 1437-1443.
28. Barron, M. A., D. Gao, K. L. Springer, J. A. Patterson, M. W. Brunvand, P. A. McSweeney, C. Zeng, A. E. Barón, and A. Weinberg. 2009. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 49: 1777-1783.
29. Brown, J. A., K. Stevenson, H. T. Kim, C. Cutler, K. Ballen, S. McDonough, C. Reynolds, M. Herrera, D. Liney, V. Ho, et al. 2010. Clearance of CMV vi-remia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 115: 4111-4119.
30. Feldman, S., W. T. Hughes, and C. B. Daniel. 1975. Varicella in children with cancer: Seventy-seven cases. Pediatrics 56: 388-397.
31. Arvin, A. M. 2000. Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 6: 219-230.
32. Wiegering, V., J. Schick, M. Beer, B. Weissbrich, S. Gattenlöhner, H. J. Girschick, J. Liese, P. G. Schlegel, and M. Eyrich. 2011. Varicella-zoster virus infections in immunocompromised patients-a single centre 6-years analysis. BMC Pediatr. 11: 31.
33. Tomblyn, M., T. Chiller, H. Einsele, R. Gress, K. Sepkowitz, J. Storek, J. R. Wingard, J. A. Young, and M. J. Boeckh; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. 2009. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant. 15: 1143-1238.
34. Burke, B. L., R. W. Steele, O. W. Beard, J. S. Wood, T. D. Cain, and D. J. Marmer. 1982. Immune responses to varicella-zoster in the aged. Arch. Intern. Med. 142: 291-293.
35. Quinnan, G. V., Jr., N. Kirmani, A. H. Rook, J. F. Manischewitz, L. Jackson, G. Moreschi, G. W. Santos, R. Saral, and W. H. Burns. 1982. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307: 7-13.
36. Reusser, P., S. R. Riddell, J. D. Meyers, and P. D. Greenberg. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78: 1373-1380.
37. Levin, M. J., J. G. Smith, R. M. Kaufhold, D. Barber, A. R. Hayward, C. Y. Chan, I. S. Chan, D. J. Li, W. Wang, P. M. Keller, et al. 2003. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J. Infect. Dis. 188: 1336-1344.
38. + T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur. J. Immunol. 37: 3393-3403.
39. Ljungman, P., H. Wilczek, G. Gahrton, A. Gustavsson, G. Lundgren, B. Lönnqvist, O. Ringdén, and B. Wahren. 1986. Long-term acyclovir prophy laxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant. 1: 185-192.
40. Selby, P. J., R. L. Powles, D. Easton, T. J. Perren, K. Stolle, B. Jameson, A. P. Fiddian, Y. Tryhorn, and H. Stern. 1989. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br. J. Cancer 59: 434-438.
41. Distler, E., E. Schnürer, E. Wagner, C. von Auer, B. Plachter, D. Wehler, C. Huber, K. Kolbe, R. G. Meyer, and W. Herr. 2008. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic trans plantation requires symptomatic virus reactivation. Biol. Blood Marrow Transplant. 14: 1417-1424.
42. Merindol, N., M. A. Champagne, M. Duval, and H. Soudeyns. 2011. CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood 118: 4480-4488.
43. Dalle, J. H., M. Duval, A. Moghrabi, E. Wagner, M. F. Vachon, S. Barrette, M. Bernstein, J. Champagne, M. David, J. Demers, et al. 2004. Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant. 33: 605-611.
44. Renoult, E., M. J. Clermont, V. Phan, C. Buteau, C. Alfieri, and B. Tapiero. 2008. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr. Transplant. 12: 420-425.
45. Appay, V., R. A. van Lier, F. Sallusto, and M. Roederer. 2008. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 73: 975-983.
46. Kimmig, S., G. K. Przybylski, C. A. Schmidt, K. Laurisch, B. Möwes, A. Radbruch, and A. Thiel. 2002. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J. Exp. Med. 195: 789-794.
47. + T cells reveals conserved precursor frequencies. Blood 115: 3718-3725.
48. Kern, F., N. Faulhaber, C. Frömmel, E. Khatamzas, S. Prösch, C. Schönemann, I. Kretzschmar, R. Volkmer-Engert, H. D. Volk, and P. Reinke. 2000. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30: 1676-1682.
49. Landolfo, S., M. Gariglio, G. Gribaudo, and D. Lembo. 2003. The human cy-tomegalovirus. Pharmacol. Ther. 98: 269-297.
50. Kondo, E., Y. Akatsuka, K. Kuzushima, K. Tsujimura, S. Asakura, K. Tajima, Y. Kagami, Y. Kodera, M. Tanimoto, Y. Morishima, and T. Takahashi. 2004. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 103: 630-638.
51. Shearer, W. T., H. M. Rosenblatt, R. S. Gelman, R. Oyomopito, S. Plaeger, E. R. Stiehm, D. W. Wara, S. D. Douglas, K. Luzuriaga, E. J. McFarland, et al Pediatric AIDS Clinical Trials Group. 2003. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J. Allergy Clin. Immunol. 112: 973-980.
52. Rénard, C., V. Barlogis, V. Mialou, C. Galambrun, D. Bernoux, M. P. Goutagny, L. Glasman, A. D. Loundou, F. Poitevin-Later, F. Dignat-George, et al. 2011. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br. J. Haematol. 152: 322-330.
53. Surh, C. D., and J. Sprent. 2008. Homeostasis of naive and memory T cells. Immunity 29: 848-862.
54. Krenger, W., B. R. Blazar, and G. A. Holländer. 2011. Thymic T-cell development in allogeneic stem cell transplantation. Blood 117: 6768-6776.
55. Harari, A., V. Dutoit, C. Cellerai, P. A. Bart, R. A. Du Pasquier, and G. Pantaleo. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211: 236-254.
56. Kern, F., E. Khatamzas, I. Surel, C. Frömmel, P. Reinke, S. L. Waldrop, L. J. Picker, and H. D. Volk. 1999. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur. J. Immunol. 29: 2908-2915.
57. Gamadia, L. E., R. J. Rentenaar, P. A. Baars, E. B. Remmerswaal, S. Surachno, J. F. Weel, M. Toebes, T. N. Schumacher, I. J. ten Berge, and R. A. van Lier. 2001. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 98: 754-761.
58. Kern, F., T. Bunde, N. Faulhaber, F. Kiecker, E. Khatamzas, I. M. Rudawski, A. Pruss, J. W. Gratama, R. Volkmer-Engert, R. Ewert, et al. 2002. Cytomega-lovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185: 1709-1716.
59. Asanuma, H., M. Sharp, H. T. Maecker, V. C. Maino, and A. M. Arvin. 2000. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J. Infect. Dis. 181: 859-866.
60. + T cell response to IE62, by use of IE62 peptides after varicella vaccination. J. Infect. Dis. 188: 40-52.
61. Cohen, G., S. L. Carter, K. I. Weinberg, B. Masinsin, E. Guinan, J. Kurtzberg, J. E. Wagner, N. A. Kernan, and R. Parkman. 2006. Antigen-specific T-lymphocyte function after cord blood transplantation. Biol. Blood Marrow Transplant. 12: 1335-1342.
62. Montesinos, P., J. Sanz, S. Cantero, I. Lorenzo, G. Mart́in, S. Saavedra, J. Palau, M. Romero, A. Montava, L. Senent, et al. 2009. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol. Blood Marrow Transplant. 15: 730-740.
63. Ruell, J., C. Barnes, K. Mutton, B. Foulkes, J. Chang, J. Cavet, M. Guiver, L. Menasce, M. Dougal, and R. Chopra. 2007. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 40: 55-61.
64. Sester, M., B. C. Gärtner, U. Sester, M. Girndt, N. Mueller-Lantzsch, and H. Köhler. 2003. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 76: 1229-1230.
65. Benz, C., O. Utermöhlen, A. Wulf, B. Villmow, V. Dries, T. Goeser, U. Koszinowski, and D. H. Busch. 2002. Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patients. Gastroenterology 122: 1201-1215.
66. Ziemann, M., S. Krueger, A. B. Maier, A. Unmack, S. Goerg, and H. Hennig. 2007. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 47: 1972-1983.
67. Farnault, L., H. Chambost, C. Zandotti, F. Mallet, V. Barlogis, C. Galambrun, G. Michel, and D. Olive. 2012. Early recovery of immunity after cord-blood transplantation in children: qualitative features and impact of cytomegalovirus infection. Acta Haematol. 128: 7-16.
68. + T cell responses to cytomega-lovirus and EBV. J. Immunol. 181: 7853-7862.
69. Hanley, P. J., C. R. Cruz, B. Savoldo, A. M. Leen, M. Stanojevic, M. Khalil, W. Decker, J. J. Molldrem, H. Liu, A. P. Gee, et al. 2009. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114: 1958-1967.
70. Kennedy, P. G., E. Grinfeld, and J. W. Gow. 1998. Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc. Natl. Acad. Sci. USA 95: 4658-4662.
71. Ludwig, B., F. B. Kraus, R. Allwinn, S. Keim, H. W. Doerr, and S. Buxbaum. 2006. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination. Infection 34: 222-226.
72. Dobec, M., W. Bossart, F. Kaeppeli, and J. Mueller-Schoop. 2008. Serology and serum DNA detection in shingles. Swiss Med. Wkly. 138: 47-51.
73. Baiker, A., R. Haase, J. Eberle, M. G. Vizoso Pinto, K. I. Pfrepper, A. Petrich, L. Deml, H. Campe, H. Nitschko, and G. Jaeger. 2010. Early detection of Varicella-Zoster virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report. Virol. J. 7: 54.
74. Vafai, A., Z. Wroblewska, and L. Graf. 1990. Antigenic cross-reaction between a varicella-zoster virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid protein. Virus Res. 15: 163-174.
75. Kitamura, K., J. Namazue, H. Campo-Vera, T. Ogino, and K. Yamanishi. 1986. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB. Vi-rology 149: 74-82.
76. Edson, C. M., B. A. Hosler, R. A. Respess, D. J. Waters, and D. A. Thorley-Lawson. 1985. Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein. J. Virol. 56: 333-336.
77. Sandalova, E., D. Laccabue, C. Boni, A. T. Tan, K. Fink, E. E. Ooi, R. Chua, B. Shafaeddin Schreve, C. Ferrari, and A. Bertoletti. 2010. Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog. 6: e1001051.
78. Malavige, G. N., L. T. Rohanachandra, L. Jones, L. Crack, M. Perera, N. Fernando, D. Guruge, and G. S. Ogg. 2010. IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. Br. J. Cancer 102: 727-730.
79. Meyers, J. D., N. Flournoy, and E. D. Thomas. 1980. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J. Infect. Dis. 141: 479-487.
80. Wilson, A., M. Sharp, C. M. Koropchak, S. F. Ting, and A. M. Arvin. 1992. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J. Infect. Dis. 165: 119-126.
81. Abate, D., S. Cesaro, S. Cofano, M. Fiscon, A. Saldan, S. Varotto, C. Mengoli, M. Pillon, E. Calore, M. A. Biasolo, et al. 2012. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 93: 536-542.